SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$36.21 USD
-0.46 (-1.25%)
Updated Jun 18, 2024 04:00 PM ET
After-Market: $36.15 -0.06 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
SpringWorks Therapeutics [SWTX]
Reports for Purchase
Showing records 41 - 60 ( 190 total )
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology -AACR 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
As The Dust Settles -- Sifting Through The Biotech Carnage, We See Opportunity
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Nirogacestat Gets Priority Review; 2022 Financials; Raising PT to $105
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
The Countdown Begins for Niro in Desmoid Tumors
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
2023 TKI Outlook: Bullseye: What?s a Hit in Targeted Oncology in 2023?
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Springing Towards a Commercial Launch in 2023
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology- ASH Day 3 Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
3Q22 Financials Reported; Modulating PT to $99, Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R